Institute of Hematology & Blood Diseases Hospital, China: Thrombocytopenia trials

The registry lists 25 Thrombocytopenia studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 19 are open to participants now and 0 have results posted.

Phase 2 19Phase 3 1Phase 4 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional TrialRecruitingNCT06992128Phase 2
• An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune ThrombocytopeniaRecruitingNCT06799611Phase 2
• A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITPRecruitingNCT06658834Phase 2
• Avatrombopag in the Treatment of Pediatric Immune ThrombocytopeniaRecruitingNCT06281327Phase 2
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06094881Phase 2
• Anti-CD38 Antibody Treating Evans SyndromeRecruitingNCT06014775Phase 2
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune ThrombocytopeniaRecruitingNCT05995054Phase 2
• Anti-CD38 Antibody Treating APS With ThrombocytopeniaRecruitingNCT05983952Phase 2
• TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT05718856Phase 4
• Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential ThrombocythemiaRecruitingNCT05395507Phase 2
• Herombopag for Chemotherapy-induced ThrombocytopeniaRecruitingNCT05236582Phase 2
• Avatrombopag for Chemotherapy-induced ThrombocytopeniaRecruitingNCT05218226Phase 2
• A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune ThrombocytopeniaRecruitingNCT05214391Phase 2
• Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary ThrombocytopeniaRecruitingNCT05199909Phase 2
• TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesRecruitingNCT04915482Phase 2/3
• TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 YearsRecruitingNCT04890041Not applicable
• Eltrombopag for Chemotherapy-induced ThrombocytopeniaRecruitingNCT04600960Phase 2
• Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential ThrombocythemiaRecruitingNCT04226950Phase 2
• Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia PatientsRecruitingNCT03998059
• A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaActive, not recruitingNCT06199089Phase 2
• A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaCompletedNCT05694767Phase 2
• A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP PtsCompletedNCT05583838Phase 4
• A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune ThrombocytopeniaActive, not recruitingNCT05562882Phase 2
• Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune ThrombocytopeniaCompletedNCT04014166Not applicable
• Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML PatientsCompletedNCT02267993Phase 4